Scientists Develop a Biological Artificial Pancreas for Chronic Disease
- Feb 9
- 2 min read
In a landmark achievement for chronic disease management, researchers from the Technion–Israel Institute of Technology, in collaboration with leading U.S. institutions like MIT and Harvard, have developed a "living" biological implant that functions as an autonomous artificial pancreas. This biosensor-based system is designed to continuously monitor blood sugar levels and synthesize insulin directly within the body, potentially eliminating the need for daily injections or external pumps.
The primary breakthrough lies in overcoming immune rejection, a long-standing hurdle for medical implants. The team developed a "crystalline shield"—a protective shell made of engineered therapeutic crystals—that isolates the living cells inside the implant. This shield prevents the immune system from recognizing the device as a foreign object, allowing it to function reliably for several years. While currently tested on mice and primates, the successful regulation of glucose levels has paved the way for human clinical trials.
Beyond diabetes, experts suggest this "closed-loop platform" could be adapted to treat other chronic conditions requiring constant biological drug delivery, such as hemophilia and various metabolic or genetic disorders.
In parallel, recent research highlights from Diabetes UK underscore further progress in "encapsulation" technology. A study by the biotech company Encellin demonstrated that a new device allowed lab-made beta cells to survive in humans for four months. Unlike previous attempts where thick scar tissue starved the cells, this new device encouraged the growth of healthy blood vessels, providing the cells with essential oxygen and nutrients.
The medical community is also expanding its focus to the holistic health of patients. New data shows that weight stigma significantly impacts both mental and physical health, with patients experiencing weight-based discrimination showing higher rates of depressive symptoms and markers linked to heart disease. Additionally, scientists have identified a chemical "signature" of 235 small molecules in the blood that can predict Type 2 diabetes risk more accurately than traditional factors like age or current blood sugar levels, offering a path toward highly tailored prevention methods.
🔖 Sources
Keywords: Biological Artificial Pancreas
Biological Artificial Pancreas
Comments